Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more
Hofseth BioCare ASA (HOFBF) - Total Liabilities
Latest total liabilities as of December 2025: $469.81 Million USD
Based on the latest financial reports, Hofseth BioCare ASA (HOFBF) has total liabilities worth $469.81 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hofseth BioCare ASA - Total Liabilities Trend (2010–2025)
This chart illustrates how Hofseth BioCare ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hofseth BioCare ASA Competitors by Total Liabilities
The table below lists competitors of Hofseth BioCare ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Groupe Partouche SA
PA:PARP
|
France | €572.21 Million |
|
Kingsmen Resources Ltd
OTCQB:KNGRF
|
USA | $231.17K |
|
Grande Hospitality Real Estate Investment Trust
BK:GAHREIT
|
Thailand | ฿60.68 Million |
|
Wetteri
HE:WETTERI
|
Finland | €156.73 Million |
|
FAIR ISAAC
BE:FRI
|
Germany | €2.68 Billion |
|
Telefield Inc
KQ:091440
|
Korea | ₩68.19 Billion |
|
Tayih Lun An Co Ltd
TWO:8107
|
Taiwan | NT$1.42 Billion |
|
Baumer S.A
SA:BALM3
|
Brazil | R$117.25 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Hofseth BioCare ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hofseth BioCare ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hofseth BioCare ASA (2010–2025)
The table below shows the annual total liabilities of Hofseth BioCare ASA from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $469.81 Million | +67.75% |
| 2024-12-31 | $280.07 Million | -19.75% |
| 2023-12-31 | $348.98 Million | +32.69% |
| 2022-12-31 | $263.00 Million | -4.57% |
| 2021-12-31 | $275.60 Million | +41.06% |
| 2020-12-31 | $195.37 Million | +11.47% |
| 2019-12-31 | $175.26 Million | +71.99% |
| 2018-12-31 | $101.90 Million | -30.75% |
| 2017-12-31 | $147.16 Million | +39.10% |
| 2016-12-31 | $105.79 Million | -34.21% |
| 2015-12-31 | $160.80 Million | +15.75% |
| 2014-12-31 | $138.92 Million | -2.89% |
| 2013-12-31 | $143.05 Million | +32.55% |
| 2012-12-31 | $107.92 Million | +185.20% |
| 2011-12-31 | $37.84 Million | +103.55% |
| 2010-12-31 | $18.59 Million | -- |